Cypherpunk Technologies Inc. (FRA:5MC)

Germany flag Germany · Delayed Price · Currency is EUR
0.6200
-0.0300 (-4.62%)
At close: Mar 18, 2026
Market Cap51.28M +271.8%
Revenue (ttm)n/a
Net Income4.11M
EPS0.06
Shares Outn/a
PE Ratio12.49
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,388
Average Volume1,850
Open0.6550
Previous Close0.6500
Day's Range0.6200 - 0.7150
52-Week Range0.0280 - 3.0000
Betan/a
RSI50.45
Earnings DateMay 13, 2026

About Cypherpunk Technologies

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorec... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 52
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5MC

Financial Performance

Financial numbers in USD Financial Statements

News

Cypherpunk Reports Full Year 2025 Financial Results

CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the year ended December 31, 2025.

12 days ago - PRNewsWire

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Cypherpunk expands its holdings with new $5M investment in Zcash company, ZODL, alongside key investors including a16z, Winklevoss Capital, Coinbase, Paradigm, Chapter One, David Friedberg , Balaji Sr...

20 days ago - PRNewsWire

Cypherpunk Adds Arjun Khemani as Strategic Advisor

CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), the privacy technology company, today announced that Arjun Khemani has joined the company as...

2 months ago - PRNewsWire

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

CAMBRIDGE, Mass., Dec. 30, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), the privacy-focused technology company, today announced a significant expansion of its corpo...

3 months ago - PRNewsWire

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

CAMBRIDGE, Mass. , Dec. 19, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that Josh Swihart, Chief Executive Officer of Electric Coin Company (ECC), has joined the c...

3 months ago - PRNewsWire

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

3 months ago - Seeking Alpha

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

CAMBRIDGE, Mass. , Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Co...

3 months ago - PRNewsWire

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass. , Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer ...

4 months ago - PRNewsWire

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass...

4 months ago - PRNewsWire

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to ...

5 months ago - PRNewsWire

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

CAMBRIDGE, Mass. , Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has cl...

6 months ago - PRNewsWire

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in...

6 months ago - PRNewsWire

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

CAMBRIDGE, Mass. , Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it wi...

6 months ago - PRNewsWire

Leap Therapeutics Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass. , Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

8 months ago - PRNewsWire

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated p...

9 months ago - PRNewsWire

Leap Therapeutics Reports First Quarter 2025 Financial Results

CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...

11 months ago - PRNewsWire

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, ...

1 year ago - PRNewsWire

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass.

1 year ago - PRNewsWire

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Leap Therapeutics (NASDAQ:LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard ...

1 year ago - Seeking Alpha

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics, Inc.  LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experi...

1 year ago - Benzinga

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.

1 year ago - PRNewsWire

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS  in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy St...

1 year ago - PRNewsWire

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 level...

1 year ago - PRNewsWire

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a ...

1 year ago - Seeking Alpha

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dou...

1 year ago - PRNewsWire